Mauro Zukin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mauro Zukin has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
- Clarissa Baldotto
Instituto D’Or de Pesquisa e Ensino - Department of Clinical Oncology , Rio de Janeiro
3 shared publications - Clarissa Mathias
Oncoclínicas, Salvador (BA), Brasil
3 shared publications - Eldsamira Mascarenhas
Instituto D'Or de ensino e pesquisa, Rio de Janeiro, Brazil
3 shared publications - Luiz Henrique Araujo
Department of Medical Oncology Instituto Nacional de Câncer Rio de Janeiro Brazil
3 shared publications - Vladmir Cláudio Cordeiro de Lima
A.C. Camargo Cancer Center, Sao Paulo, Brazil
3 shared publications - Ana Caroline Zimmer Gelatti
PUC-RS, Porto Alegre, Brazil
2 shared publications
Latest Publications
- Open Access
- 9 January 2025
- Published by Georg Thieme Verlag KG in Brazilian Journal of Oncology
- Vol. 21 (CP)
Crizotinib-Related Aseptic Abscesses in Lung Adenocarcinoma and ROS1-Gene Rearrangement: A Case Report
Crizotinib is a multi-tyrosine kinase inhibitor (mTKI) with efficacy in treating c-ROS oncogene 1-positive non-small cell lung cancer (NSCLC). The association between this TKI and the development of renal cysts is well established, although data on the formation of aseptic abscesses is scarce. We report a case of a patient with ROS1-positive NSCLC treated with crizotinib who developed multiple renal and extrarenal cysts and aseptic abscesses associated with a quick resolution of these lesions after the discontinuation of the TKI therapy. We aim to report a rare presentation of a drug-related adverse event with an unusual behavior.
- 9 January 2025
- Published by Georg Thieme Verlag KG in Brazilian Journal of Oncology
- Vol. 21 (CP)
Open AccessCrizotinib-Related Aseptic Abscesses in Lung Adenocarcinoma and ROS1-Gene Rearrangement: A Case Report
Crizotinib is a multi-tyrosine kinase inhibitor (mTKI) with efficacy in treating c-ROS oncogene 1-positive non-small cell lung cancer (NSCLC). The association between this TKI and the development of renal cysts is well established, although data on the formation of aseptic abscesses is scarce. We report a case of a patient with ROS1-positive NSCLC treated with crizotinib who developed multiple renal and extrarenal cysts and aseptic abscesses associated with a quick resolution of these lesions after the discontinuation of the TKI therapy. We aim to report a rare presentation of a drug-related adverse event with an unusual behavior.
- Open Access
- 12 December 2024
- Published by Sociedade Brasileira de Pneumologia e Tisiologia in Jornal Brasileiro de Pneumologia
- Vol. 50 (6) , e20240228
Durvalumab as consolidation therapy in patients who received chemoradiotherapy for unresectable stage III NSCLC: Real-world data from an expanded access program in Brazil (LACOG 0120)
Objective: The PACIFIC trial established standard therapy for patients with unresectable stage III NSCLC who did not progress after platinum-based concurrent chemoradiation therapy. However, real-world data, particularly from Latin America, remain limited. The LACOG 0120 study aimed to evaluate the efficacy and safety of consolidation therapy with durvalumab in a real-world setting in Brazil. Methods: Patients with unresectable stage III NSCLC who received chemoradiotherapy followed by durvalumab consolidation therapy through an expanded access program were evaluated. The primary objective was to assess progression-free survival (PFS). Secondary endpoints included overall survival (OS), treatment compliance, and safety, with a focus on the incidence and severity of immune-mediated adverse events (NCT04948411). Results: Thirty-one patients from seven centers were evaluated. Median follow-up was 50.3 months (95% CI: 48.6–54.4). Median PFS was 9.9 months (95% CI: 7.3–52.4), with a 36 month-PFS of 34.5% (95% CI: 17.7–52.1). Median OS was 34.9 months (95% CI: 26.0–NR), and the 36 month-OS was 46.3% (95% CI: 25.7–64.6). Durvalumab was administered for a median of 17 cycles (10 to 24), with 45.2% of patients completing the planned therapy. The main reason for discontinuation was disease progression. Treatment-related adverse events of any grade occurred in 12 patients (38.7%), with grade 3 events reported in two (6.5%). Pneumonitis was observed in 4 patients (12.9%) – grade 3 in 1 patient. Conclusions: PFS was lower in this analysis compared to the PACIFIC trial; however, OS was similar, indicating comparable efficacy in a real-world setting among Brazilian patients with unresectable stage III NSCLC. No new safety concerns were identified.
- 12 December 2024
- Published by Sociedade Brasileira de Pneumologia e Tisiologia in Jornal Brasileiro de Pneumologia
- Vol. 50 (6) , e20240228
Open AccessDurvalumab as consolidation therapy in patients who received chemoradiotherapy for unresectable stage III NSCLC: Real-world data from an expanded access program in Brazil (LACOG 0120)
Objective: The PACIFIC trial established standard therapy for patients with unresectable stage III NSCLC who did not progress after platinum-based concurrent chemoradiation therapy. However, real-world data, particularly from Latin America, remain limited. The LACOG 0120 study aimed to evaluate the efficacy and safety of consolidation therapy with durvalumab in a real-world setting in Brazil. Methods: Patients with unresectable stage III NSCLC who received chemoradiotherapy followed by durvalumab consolidation therapy through an expanded access program were evaluated. The primary objective was to assess progression-free survival (PFS). Secondary endpoints included overall survival (OS), treatment compliance, and safety, with a focus on the incidence and severity of immune-mediated adverse events (NCT04948411). Results: Thirty-one patients from seven centers were evaluated. Median follow-up was 50.3 months (95% CI: 48.6–54.4). Median PFS was 9.9 months (95% CI: 7.3–52.4), with a 36 month-PFS of 34.5% (95% CI: 17.7–52.1). Median OS was 34.9 months (95% CI: 26.0–NR), and the 36 month-OS was 46.3% (95% CI: 25.7–64.6). Durvalumab was administered for a median of 17 cycles (10 to 24), with 45.2% of patients completing the planned therapy. The main reason for discontinuation was disease progression. Treatment-related adverse events of any grade occurred in 12 patients (38.7%), with grade 3 events reported in two (6.5%). Pneumonitis was observed in 4 patients (12.9%) – grade 3 in 1 patient. Conclusions: PFS was lower in this analysis compared to the PACIFIC trial; however, OS was similar, indicating comparable efficacy in a real-world setting among Brazilian patients with unresectable stage III NSCLC. No new safety concerns were identified.
- 1 November 2020
- Published by Elsevier in Clinical Lung Cancer
- Vol. 21 (6) , e511-e515
Real-World Prevalence of PD-L1 Expression Among Tumor Samples From Patients With Non–Small-Cell Lung Cancer
- 1 November 2020
- Published by Elsevier in Clinical Lung Cancer
- Vol. 21 (6) , e511-e515
Real-World Prevalence of PD-L1 Expression Among Tumor Samples From Patients With Non–Small-Cell Lung Cancer
- Open Access
Lung Cancer and the COVID-19 pandemic: Recommendations from the Brazilian Thoracic Oncology Group
New cases of the novel coronavirus disease 2019 (COVID-19), also known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), continue to rise worldwide following the declaration of a pandemic by the World Health Organization (WHO). The current ...
Open AccessLung Cancer and the COVID-19 pandemic: Recommendations from the Brazilian Thoracic Oncology Group
New cases of the novel coronavirus disease 2019 (COVID-19), also known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), continue to rise worldwide following the declaration of a pandemic by the World Health Organization (WHO). The current ...
- Open Access
- 1 February 2018
- Published by FapUNIFESP (SciELO) in Jornal Brasileiro de Pneumologia
- Vol. 44 (1) , 55-64
Lung cancer in Brazil
Lung cancer is one of the most incident types of cancer and a leading cause of cancer mortality in Brazil. We reviewed the current status of lung cancer by searching relevant data on prevention, diagnosis, and treatment in the country. This review highlights several issues that need to be addressed, including smoking control, patient lack of awareness, late diagnosis, and disparities in the access to cancer health care facilities in Brazil. We propose strategies to help overcome these limitations and challenge health care providers, as well as the society and governmental representatives, to work together and to take a step forward in fighting lung cancer.
- 1 February 2018
- Published by FapUNIFESP (SciELO) in Jornal Brasileiro de Pneumologia
- Vol. 44 (1) , 55-64
Open AccessLung cancer in Brazil
Lung cancer is one of the most incident types of cancer and a leading cause of cancer mortality in Brazil. We reviewed the current status of lung cancer by searching relevant data on prevention, diagnosis, and treatment in the country. This review highlights several issues that need to be addressed, including smoking control, patient lack of awareness, late diagnosis, and disparities in the access to cancer health care facilities in Brazil. We propose strategies to help overcome these limitations and challenge health care providers, as well as the society and governmental representatives, to work together and to take a step forward in fighting lung cancer.
- 1 September 2015
- Published by Elsevier in Lung Cancer
- Vol. 89 (3) , 274-279
Carboplatin plus pemetrexed offers superior cost-effectiveness compared to pemetrexed in patients with advanced non-small cell lung cancer and performance status 2
- 1 September 2015
- Published by Elsevier in Lung Cancer
- Vol. 89 (3) , 274-279
Carboplatin plus pemetrexed offers superior cost-effectiveness compared to pemetrexed in patients with advanced non-small cell lung cancer and performance status 2